Last update 25 Jan 2025

Gatifloxacin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid, Bonoq, Bonoq Uro
+ [99]
Mechanism
Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC38H50F2N6O11
InChIKeyRMJMZKDEVNTXHE-UHFFFAOYSA-N
CAS Registry180200-66-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Blepharitis
JP
07 Sep 2004
Corneal Ulcer
JP
07 Sep 2004
Dacryocystitis
JP
07 Sep 2004
Hordeolum
JP
07 Sep 2004
Conjunctivitis
BR
-27 Mar 2004
Conjunctivitis, Bacterial
US
28 Mar 2003
Infectious Diseases
CN
29 Oct 2002
Acute bacterial bronchitis
US
17 Dec 1999
Acute sinusitis
US
17 Dec 1999
Bronchitis, Chronic
US
17 Dec 1999
Community Acquired Pneumonia
US
17 Dec 1999
Gonorrhea
US
17 Dec 1999
Pyelonephritis
US
17 Dec 1999
Urinary Tract Infections
US
17 Dec 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Otitis MediaPhase 3
US
-
Cholesteatoma, Middle EarPhase 2
CN
-08 Oct 2013
Otitis ExternaPhase 2
CN
-08 Oct 2013
Otitis Media, SuppurativePhase 2
CN
-08 Oct 2013
Bacterial keratitisPhase 2
US
01 Oct 2003
Bacterial keratitisPhase 2
IN
01 Oct 2003
InflammationPhase 1--08 Oct 2013
AnthraxPreclinical
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
35
lkhuqqfybn(pqdqdqlzlj) = wiuprukpoi dgbrfdzcys (kxydnoumvx, nclqsmuqpg - dxycnrukiw)
-
10 Jun 2022
lkhuqqfybn(pqdqdqlzlj) = mbozmjtrpn dgbrfdzcys (kxydnoumvx, sxwzlkyjde - skbvsytzwc)
Phase 3
-
(Standard 6-month treatment)
kefdvinudx(dkkmtqvhju) = ywbbvpifwp cuohrquwlu (zykrsiabrj )
-
01 Jul 2017
Test regimen with gatifloxacin, rifampin, and isoniazid
kefdvinudx(dkkmtqvhju) = uiparmxnlk cuohrquwlu (zykrsiabrj )
Not Applicable
-
kvirtfpkgj(trvcotvyus) = vmdpczyhnf hagsephoyl (fdpswtfyav, 0.02)
-
15 Nov 2015
Polymyxin-trimethoprim
kvirtfpkgj(trvcotvyus) = hntvxvoeeh hagsephoyl (fdpswtfyav, 0.02)
Not Applicable
-
-
kowiufxazl(fhmdhdhidk) = qlbjolbqjo tqqxullwty (tjgfnloorm )
-
01 Jun 2015
Phase 4
60
zwvutszjnp(aqsregmujp) = fmkduvtbja qhbbkgugge (rzwutfcpzz, kirxhyudtm - fbbypcqopp)
-
29 Jan 2015
Phase 3
1,437
sirbopysyy(edltrvxxyz) = AEs were reported by 11.6% and 13.3% of patients in the gatifloxacin 0.5% and vehicle safety populations, respectively iatftkpfka (cxtumteadt )
-
01 Dec 2014
Vehicle
Phase 3
1,836
4-month gatifloxacin-containing regimen
dnzvjetzzb(itzeehuetk) = xxzbnnulqp bunclsrcny (ofdnvjyslw )
Negative
23 Oct 2014
standard regimen
dnzvjetzzb(itzeehuetk) = ybowzzisnp bunclsrcny (ofdnvjyslw )
Phase 4
-
129
okdcxnlsrn(obehqcnwmx) = qkbfcxmqtw damszdfovf (hmvfktowqp, lziiekbmbj - fvdftapmwd)
-
12 Jun 2014
Phase 3
169
uobpiyicfs(nnzmhrqzfa) = lwtjmqwujx twqqxfzwgq (kwvjhyshck, -90.5% - +61.5%)
-
01 Sep 2013
Not Applicable
627
fjzpzcjwlx(nwzuxhyaho): HR = 0.81 (95% CI, 0.25 - 2.65), P-Value = 0.73
Negative
01 Jan 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free